Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study

• Nao Suzuki,

  Roles Formal analysis, Writing – original draft

  Affiliation Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan

  ⨯
• Nobuhiro Ooba ,

  Roles Formal analysis, Funding acquisition, Methodology, Writing – original draft, Writing – review & editing

  * E-mail: ooba.nobuhiro@nihon-u.ac.jp

  Affiliation Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan

  https://orcid.org/0000-0003-0579-3946

  ⨯
• Rie Nakajima,

  Roles Formal analysis, Investigation, Methodology

  Affiliation Department of Pharmacy Practice in Primary Care, Nihon University School of Pharmacy, Funabashi, Chiba, Japan

  ⨯
• Kasumi Takabatake,

  Roles Formal analysis, Investigation, Methodology

  Affiliation Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan

  ⨯
• Masahiro Saita,

  Roles Data curation, Investigation

  Affiliation Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan

  ⨯
• Eiji Kawakami,

  Roles Data curation, Investigation

  Affiliation Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan

  ⨯
• Michiyo Kawana,

  Roles Data curation, Investigation

  Affiliations Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan, Department of Pharmaceutical Sciences, Teikyo University School of Pharmacy, Itabashi-ku, Tokyo, Japan

  ⨯
• Daiki Watanabe,

  Roles Data curation, Investigation

  Affiliation Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan

  ⨯
• Hajime Hashiba

  Roles Data curation, Investigation

  Affiliation Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan

  ⨯